Altimmune Announces Positive Topline Data From IMPACT Phase 2b Study Of Pemvidutide In MASH

Altimmune (ALT) announced positive topline results from its IMPACT Phase 2b study of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), successfully meeting its primary endpoint. The study demonstrated significant MASH resolution without worsening fibrosis in 59.1% and 52.1% of participants treated with pemvidutide 1.2 mg and 1.8 mg, respectively, compared to 19.1% for placebo. Furthermore, pemvidutide showed improvements in fibrosis, with 30.6% of participants on the 1.8 mg dose achieving a 60% or greater fibrosis reduction versus 8.2% for placebo, positioning it as a promising therapeutic candidate in the MASH landscape.

Analysis

Altimmune, Inc. (ALT) has reported a significant clinical milestone with positive topline results from its IMPACT Phase 2b study of pemvidutide in MASH, successfully meeting its primary endpoint. The trial demonstrated a compelling MASH resolution rate without worsening of fibrosis, with 59.1% of participants on the 1.2 mg dose and 52.1% on the 1.8 mg dose achieving this outcome, compared to just 19.1% for placebo. While the data on fibrosis improvement showed a more modest effect in the intent-to-treat analysis (31.8% and 34.5% for the respective drug doses versus 25.9% for placebo), a separate AI-based analysis revealed a more robust anti-fibrotic signal. Specifically, this AI analysis showed that 30.6% of participants on the 1.8 mg dose achieved a fibrosis reduction of 60% or more, a stark contrast to the 8.2% observed in the placebo group. This result de-risks the asset and positions pemvidutide as a promising candidate in the competitive MASH therapeutic landscape, though the differing signals between traditional histology and AI-based fibrosis analysis will be a key point of focus moving forward.

Key Decisions for Investors

• The positive Phase 2b results represent a significant de-risking event for pemvidutide, supporting a bullish thesis for investors confident in the MASH market opportunity.
• Investors should closely monitor the nuance in the fibrosis data; while the AI-based analysis is strong, the more modest improvement seen in the traditional histological endpoint compared to placebo could be a point of concern for regulators and a key factor in future trial design.
• Attention should now shift to Altimmune's plans for a Phase 3 trial and engagement with regulatory authorities, as well as the drug's competitive positioning against other MASH therapies.